(June 20, 2017) –  Dr. Olufunmilayo (Funmi) Olopade, a native of Nigeria and founding director of the Center for Clinical Cancer Genetics at the University of Chicago, has dedicated her career to unraveling breast cancer biology in women of African descent. Her pioneering research, published in leading scientific journals, has shown that the disease “hits earlier and harder” in Africa than among Caucasian women in the United States. BVGH’s new African Access Initiative (AAI) will help address the cancer crisis and build the capacity and infrastructure needed to support further research on Africa’s cancer landscape and clinical trials of existing and new treatments. Dr. Olopade and Dr. Pol Vandenbroucke, Vice President of the Medical Strategy at Pfizer, will join BVGH’s Board of Directors to strengthen its expertise in oncology and healthcare delivery in Africa. Click here to read more.